Audra Emily Praskwiecz, APRN, FNP-BC

Audra Praskwiecz practices at H Lee Moffitt Cancer Center & Research Institute I - HOPD in Tampa, Florida.

Audra Praskwiecz's NPI, 1154809341, was assigned on July 31, 2018. Audra Praskwiecz holds Florida license APRN11008320.

Audra Praskwiecz's primary practice is H Lee Moffitt Cancer Center & Research Institute I - HOPD, at 10901 McKinley Dr, Tampa, FL 33612.

Audra Praskwiecz's primary practice is H Lee Moffitt Cancer Center & Research Institute I - HOPD in Tampa, Florida. Audra Praskwiecz is also affiliated with Moffitt Cancer Hospital. The medical group on file is Moffitt Cancer Center. Dmand AI also links Audra Praskwiecz to 1 more group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Audra Praskwiecz practices, 3 sites in all. Vendor and product names are available with a free account.

Nurse practitioner is Audra Praskwiecz's primary specialty in the NPI Registry, under taxonomy code 363L00000X. Dmand AI has Audra Praskwiecz's licenses on file in 2 states: Florida and West Virginia.

CMS data shows 13 Medicare services from Audra Praskwiecz across 1 procedure code in 2024, for 20 Medicare patients. Medicare paid $1,039 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 20 Medicare patients who saw Audra Praskwiecz in 2024. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 3.76, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Audra Praskwiecz's median patient age at 70, with 47% women.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Audra Praskwiecz for performance year 2024, reported as part of a group. Audra Praskwiecz accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 1 general payment to Audra Praskwiecz from 1 drug or device company in 2024. Food and beverage make up the largest share, 100% of the total. Dexcom, Inc. paid the most, $24.